Last reviewed · How we verify
remimazolam combined with propofol and alfentanil
remimazolam combined with propofol and alfentanil is a Small molecule drug developed by First Affiliated Hospital of Zhejiang University. It is currently FDA-approved.
Remimazolam, combined with propofol and alfentanil, is a marketed anesthetic agent developed by the First Affiliated Hospital of Zhejiang University. The key composition patent expires in 2028, providing a strong barrier to generic competition and maintaining market exclusivity. The primary risk is the lack of revenue data, which makes it challenging to assess the drug's commercial performance and market share.
At a glance
| Generic name | remimazolam combined with propofol and alfentanil |
|---|---|
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Remimazolam for Bronchoscopy in High-Risk Patients (PHASE4)
- A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined With Alfentanil for Anesthesia in Thoracic Surgery (PHASE4)
- Efficacy and Safety Profile of Remimazolam-alfentanil Combination for ERCP Sedation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- remimazolam combined with propofol and alfentanil CI brief — competitive landscape report
- remimazolam combined with propofol and alfentanil updates RSS · CI watch RSS
- First Affiliated Hospital of Zhejiang University portfolio CI